Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Share

Statistics for the 2023 & 2024 Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist market share, created by Mordor Intelligence™ Industry Reports. Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Industry

The Europe Insulin Drugs and GLP-1 receptor agonist market is largely consolidated in nature, with the presence of leading companies like Sanofi, Novo Nordisk, and Eli Lilly. They account for more than 80% of the supply in Europe. All these companies have established their brands in the market. However, due to intense competition in the local markets for insulin, consumer penetration for their products must be achieved through constant work and effort.

Europe Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Leaders

  1. Sanofi

  2. Eli Lilly

  3. Novo Nordisk

  4. AstraZeneca

  5. Biocon

*Disclaimer: Major Players sorted in no particular order

Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Concentration

Europe Insulin and GLP-1 Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)